Pfizer remunerates Germany’s BioNTech $120M for forming mRNA flu vaccine agreement.
In mRNA field, BioNTech spearheads that heads to deals with Sanofi, Eli Lilly andGenentech and a $270 million series A.
Orchard has grabbed USD 150 Million in Series C funding for multifront late-phase gene therapy.
Artios Pharma secured USD 84 Million for clinical trials of next generation DNA damage response drugs .
U.K. based pharmaceutical company, Artios Pharma has recently bagged USD 84 Million for accelerating its DNA damage response (DDR) programs in clinical trails. Artios Pharma entered into the DDR programs after in-licensing it from Cancer Research Technology in 2016.